A CMap is a large perturbation database which provides opportunities for computational pharmacogenomics and drug design. Comparing transcriptomics profiles of targets and drugs already present in the CMap, opens up the door for finding drugs which may already be present in the market. To find possible drug candidates the transcriptomic signatures of the disease and drugs are compared, if the signatures are opposite, this indicates that the drug might inhibit the target disease.